関節リウマチ(Rheumatoid Arthritis):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Rheumatoid Arthritis - Pipeline Review, H2 2014
◆商品コード:GMDHC5653IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:1094
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD7,500 ⇒換算¥780,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における関節リウマチ(Rheumatoid Arthritis)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・関節リウマチ(Rheumatoid Arthritis)の概要
・関節リウマチ(Rheumatoid Arthritis)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・関節リウマチ(Rheumatoid Arthritis)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・関節リウマチ(Rheumatoid Arthritis)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・関節リウマチ(Rheumatoid Arthritis)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Rheumatoid Arthritis – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Rheumatoid Arthritis – Pipeline Review, H2 2014’, provides an overview of the Rheumatoid Arthritis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rheumatoid Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rheumatoid Arthritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rheumatoid Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 12
Rheumatoid Arthritis Overview 13
Therapeutics Development 14
Rheumatoid Arthritis – Therapeutics under Development by Companies 16
Rheumatoid Arthritis – Therapeutics under Investigation by Universities/Institutes 36
Rheumatoid Arthritis – Pipeline Products Glance 40
Rheumatoid Arthritis – Products under Development by Companies 44
Rheumatoid Arthritis – Products under Investigation by Universities/Institutes 71
Rheumatoid Arthritis – Companies Involved in Therapeutics Development 74
Rheumatoid Arthritis – Therapeutics Assessment 298
Drug Profiles 327
Rheumatoid Arthritis – Recent Pipeline Updates 878
Rheumatoid Arthritis – Dormant Projects 997
Rheumatoid Arthritis – Discontinued Products 1028
Rheumatoid Arthritis – Product Development Milestones 1039
Appendix 1046

[List of Tables]
Number of Products under Development for Rheumatoid Arthritis, H2 2014 61
Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H2 2014 62
Number of Products under Development by Companies, H2 2014 64
Number of Products under Development by Companies, H2 2014 (Contd..1) 65
Number of Products under Development by Companies, H2 2014 (Contd..2) 66
Number of Products under Development by Companies, H2 2014 (Contd..3) 67
Number of Products under Development by Companies, H2 2014 (Contd..4) 68
Number of Products under Development by Companies, H2 2014 (Contd..5) 69
Number of Products under Development by Companies, H2 2014 (Contd..6) 70
Number of Products under Development by Companies, H2 2014 (Contd..7) 71
Number of Products under Development by Companies, H2 2014 (Contd..8) 72
Number of Products under Development by Companies, H2 2014 (Contd..9) 73
Number of Products under Development by Companies, H2 2014 (Contd..10) 74
Number of Products under Development by Companies, H2 2014 (Contd..11) 75
Number of Products under Development by Companies, H2 2014 (Contd..12) 76
Number of Products under Development by Companies, H2 2014 (Contd..13) 77
Number of Products under Development by Companies, H2 2014 (Contd..14) 78
Number of Products under Development by Companies, H2 2014 (Contd..15) 79
Number of Products under Development by Companies, H2 2014 (Contd..16) 80
Number of Products under Development by Companies, H2 2014 (Contd..17) 81
Number of Products under Development by Companies, H2 2014 (Contd..18) 82
Number of Products under Investigation by Universities/Institutes, H2 2014 84
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 85
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 86
Comparative Analysis by Late Stage Development, H2 2014 87
Comparative Analysis by Clinical Stage Development, H2 2014 88
Comparative Analysis by Early Stage Development, H2 2014 89
Comparative Analysis by Unknown Stage Development, H2 2014 90
Products under Development by Companies, H2 2014 91
Products under Development by Companies, H2 2014 (Contd..1) 92
Products under Development by Companies, H2 2014 (Contd..2) 93
Products under Development by Companies, H2 2014 (Contd..3) 94
Products under Development by Companies, H2 2014 (Contd..4) 95
Products under Development by Companies, H2 2014 (Contd..5) 96
Products under Development by Companies, H2 2014 (Contd..6) 97
Products under Development by Companies, H2 2014 (Contd..7) 98
Products under Development by Companies, H2 2014 (Contd..8) 99
Products under Development by Companies, H2 2014 (Contd..9) 100
Products under Development by Companies, H2 2014 (Contd..10) 101
Products under Development by Companies, H2 2014 (Contd..11) 102
Products under Development by Companies, H2 2014 (Contd..12) 103
Products under Development by Companies, H2 2014 (Contd..13) 104
Products under Development by Companies, H2 2014 (Contd..14) 105
Products under Development by Companies, H2 2014 (Contd..15) 106
Products under Development by Companies, H2 2014 (Contd..16) 107
Products under Development by Companies, H2 2014 (Contd..17) 108
Products under Development by Companies, H2 2014 (Contd..18) 109
Products under Development by Companies, H2 2014 (Contd..19) 110
Products under Development by Companies, H2 2014 (Contd..20) 111
Products under Development by Companies, H2 2014 (Contd..21) 112
Products under Development by Companies, H2 2014 (Contd..22) 113
Products under Development by Companies, H2 2014 (Contd..23) 114
Products under Development by Companies, H2 2014 (Contd..24) 115
Products under Development by Companies, H2 2014 (Contd..25) 116
Products under Development by Companies, H2 2014 (Contd..26) 117
Products under Investigation by Universities/Institutes, H2 2014 118
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 119
Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 120
Rheumatoid Arthritis - Pipeline by 4SC AG, H2 2014 121
Rheumatoid Arthritis - Pipeline by AB Science, H2 2014 122
Rheumatoid Arthritis - Pipeline by AbbVie Inc., H2 2014 123
Rheumatoid Arthritis - Pipeline by Ablynx NV, H2 2014 124
Rheumatoid Arthritis - Pipeline by Acceleron Pharma, Inc., H2 2014 125
Rheumatoid Arthritis - Pipeline by AcurePharma AB, H2 2014 126
Rheumatoid Arthritis - Pipeline by Addex Therapeutics Ltd, H2 2014 127
Rheumatoid Arthritis - Pipeline by Advinus Therapeutics Ltd., H2 2014 128
Rheumatoid Arthritis - Pipeline by Aegera Therapeutics Inc., H2 2014 129
Rheumatoid Arthritis - Pipeline by Agilvax, Inc., H2 2014 130
Rheumatoid Arthritis - Pipeline by Alder Biopharmaceuticals Inc., H2 2014 131
Rheumatoid Arthritis - Pipeline by Alloksys Life Sciences BV, H2 2014 132
Rheumatoid Arthritis - Pipeline by Almirall, S.A., H2 2014 133
Rheumatoid Arthritis - Pipeline by AlphaMab Co., Ltd, H2 2014 134
Rheumatoid Arthritis - Pipeline by Amgen Inc., H2 2014 135
Rheumatoid Arthritis - Pipeline by Amura Holdings Ltd., H2 2014 136
Rheumatoid Arthritis - Pipeline by Antyra, Inc., H2 2014 137
Rheumatoid Arthritis - Pipeline by Apexigen, Inc., H2 2014 138
Rheumatoid Arthritis - Pipeline by Aprogen, Inc., H2 2014 139
Rheumatoid Arthritis - Pipeline by arGentis Pharmaceuticals, LLC, H2 2014 140
Rheumatoid Arthritis - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 141
Rheumatoid Arthritis - Pipeline by Arthrogen BV, H2 2014 142
Rheumatoid Arthritis - Pipeline by Asahi Kasei Pharma Corp., H2 2014 143
Rheumatoid Arthritis - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2014 144
Rheumatoid Arthritis - Pipeline by Astellas Pharma Inc., H2 2014 145
Rheumatoid Arthritis - Pipeline by AstraZeneca PLC, H2 2014 146
Rheumatoid Arthritis - Pipeline by Auspex Pharmaceuticals, Inc., H2 2014 147
Rheumatoid Arthritis - Pipeline by Avesthagen Limited, H2 2014 148
Rheumatoid Arthritis - Pipeline by Avexxin AS, H2 2014 149
Rheumatoid Arthritis - Pipeline by Avipep Pty Ltd, H2 2014 150
Rheumatoid Arthritis - Pipeline by Axxam SpA, H2 2014 151
Rheumatoid Arthritis - Pipeline by Biocon Limited, H2 2014 152
Rheumatoid Arthritis - Pipeline by Bioiberica, S.A., H2 2014 153
Rheumatoid Arthritis - Pipeline by Biokine Therapeutics Ltd., H2 2014 154
Rheumatoid Arthritis - Pipeline by Bionomics Limited, H2 2014 155
Rheumatoid Arthritis - Pipeline by Biotest AG, H2 2014 156
Rheumatoid Arthritis - Pipeline by BioTherapeutics Inc., H2 2014 157
Rheumatoid Arthritis - Pipeline by Biotie Therapies Corp., H2 2014 158
Rheumatoid Arthritis - Pipeline by Boehringer Ingelheim GmbH, H2 2014 159
Rheumatoid Arthritis - Pipeline by Boehringer Ingelheim Pharmaceuticals, Inc., H2 2014 160
Rheumatoid Arthritis - Pipeline by Bolder Biotechnology, Inc., H2 2014 161
Rheumatoid Arthritis - Pipeline by Bone Medical Limited, H2 2014 162
Rheumatoid Arthritis - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2014 163
Rheumatoid Arthritis - Pipeline by Bristol-Myers Squibb Company, H2 2014 164
Rheumatoid Arthritis - Pipeline by Can-Fite BioPharma Ltd., H2 2014 165
Rheumatoid Arthritis - Pipeline by CASI Pharmaceuticals Inc., H2 2014 166
Rheumatoid Arthritis - Pipeline by CEL-SCI Corporation, H2 2014 167
Rheumatoid Arthritis - Pipeline by Celgene Corporation, H2 2014 168
Rheumatoid Arthritis - Pipeline by Cellceutix Corporation, H2 2014 169
Rheumatoid Arthritis - Pipeline by Cellmid Limited, H2 2014 170
Rheumatoid Arthritis - Pipeline by Celltrion, Inc., H2 2014 171
Rheumatoid Arthritis - Pipeline by Cellular Biomedicine Group, Inc., H2 2014 172
Rheumatoid Arthritis - Pipeline by Cellworks Group, Inc., H2 2014 173
Rheumatoid Arthritis - Pipeline by CG Pharmaceuticals, Inc., H2 2014 174
Rheumatoid Arthritis - Pipeline by ChemoCentryx, Inc., H2 2014 175
Rheumatoid Arthritis - Pipeline by Chipscreen Biosciences Ltd, H2 2014 176
Rheumatoid Arthritis - Pipeline by ChironWells GmbH, H2 2014 177
Rheumatoid Arthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 178
Rheumatoid Arthritis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 179
Rheumatoid Arthritis - Pipeline by CIMAB S.A., H2 2014 180
Rheumatoid Arthritis - Pipeline by CLL Pharma, H2 2014 181
Rheumatoid Arthritis - Pipeline by Compugen Ltd., H2 2014 182
Rheumatoid Arthritis - Pipeline by Coronado Biosciences, Inc., H2 2014 183
Rheumatoid Arthritis - Pipeline by Covagen AG, H2 2014 184
Rheumatoid Arthritis - Pipeline by Creabilis SA, H2 2014 185
Rheumatoid Arthritis - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 186
Rheumatoid Arthritis - Pipeline by Diurnal Ltd, H2 2014 187
Rheumatoid Arthritis - Pipeline by Dong-A Socio Group, H2 2014 188
Rheumatoid Arthritis - Pipeline by Dynamix Pharmaceuticals Ltd., H2 2014 189
Rheumatoid Arthritis - Pipeline by Effimune SAS, H2 2014 190
Rheumatoid Arthritis - Pipeline by Eisai Co., Ltd., H2 2014 191
Rheumatoid Arthritis - Pipeline by Eli Lilly and Company, H2 2014 192
Rheumatoid Arthritis - Pipeline by Emergent BioSolutions Inc., H2 2014 193
Rheumatoid Arthritis - Pipeline by Enceladus Pharmaceuticals BV, H2 2014 194
Rheumatoid Arthritis - Pipeline by Endocyte, Inc., H2 2014 195
Rheumatoid Arthritis - Pipeline by Ensemble Therapeutics Corporation, H2 2014 196
Rheumatoid Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 197
Rheumatoid Arthritis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 198
Rheumatoid Arthritis - Pipeline by Farmacija d.o.o. Tuzla, H2 2014 199
Rheumatoid Arthritis - Pipeline by Five Prime Therapeutics, Inc., H2 2014 200
Rheumatoid Arthritis - Pipeline by Fountain Biopharma Inc., H2 2014 201
Rheumatoid Arthritis - Pipeline by Galapagos NV, H2 2014 202
Rheumatoid Arthritis - Pipeline by GeneFrontier Corporation, H2 2014 203
Rheumatoid Arthritis - Pipeline by Genentech, Inc., H2 2014 204
Rheumatoid Arthritis - Pipeline by Genor BioPharma Co., Ltd., H2 2014 205
Rheumatoid Arthritis - Pipeline by Genosco, H2 2014 206
Rheumatoid Arthritis - Pipeline by Gilead Sciences, Inc., H2 2014 207
Rheumatoid Arthritis - Pipeline by GlaxoSmithKline plc, H2 2014 208
Rheumatoid Arthritis - Pipeline by Griffin Discoveries BV, H2 2014 209
Rheumatoid Arthritis - Pipeline by Handok Inc., H2 2014 210
Rheumatoid Arthritis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 211
Rheumatoid Arthritis - Pipeline by Hanwha Chemical Co., Ltd., H2 2014 212
Rheumatoid Arthritis - Pipeline by Huabo Biopharm Co., Ltd., H2 2014 213
Rheumatoid Arthritis - Pipeline by Hutchison MediPharma Limited, H2 2014 214
Rheumatoid Arthritis - Pipeline by Idera Pharmaceuticals, Inc., H2 2014 215
Rheumatoid Arthritis - Pipeline by IMMD Inc., H2 2014 216
Rheumatoid Arthritis - Pipeline by Immune Response BioPharma, Inc., H2 2014 217
Rheumatoid Arthritis - Pipeline by ImmunoFrontier, Inc., H2 2014 218
Rheumatoid Arthritis - Pipeline by Immupharma Plc, H2 2014 219
Rheumatoid Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 220
Rheumatoid Arthritis - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014 221
Rheumatoid Arthritis - Pipeline by Innate Pharma SA, H2 2014 222
Rheumatoid Arthritis - Pipeline by Innovent Biologics, Inc., H2 2014 223
Rheumatoid Arthritis - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 224
Rheumatoid Arthritis - Pipeline by Intas Pharmaceuticals Ltd., H2 2014 225
Rheumatoid Arthritis - Pipeline by Invion Limited, H2 2014 226
Rheumatoid Arthritis - Pipeline by InvivoGen Therapeutics, H2 2014 227
Rheumatoid Arthritis - Pipeline by Johnson & Johnson, H2 2014 228
Rheumatoid Arthritis - Pipeline by Kadmon Corporation, LLC, H2 2014 229
Rheumatoid Arthritis - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 230
Rheumatoid Arthritis - Pipeline by KAHR medical Ltd., H2 2014 231
Rheumatoid Arthritis - Pipeline by Kainos Medicine, Inc., H2 2014 232
Rheumatoid Arthritis - Pipeline by Kineta, Inc., H2 2014 233
Rheumatoid Arthritis - Pipeline by LG Life Sciences, Ltd., H2 2014 234
Rheumatoid Arthritis - Pipeline by Lupin Limited, H2 2014 235
Rheumatoid Arthritis - Pipeline by Lycera Corp., H2 2014 236

[List of Figures]
Number of Products under Development for Rheumatoid Arthritis, H2 2014 61
Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H2 2014 62
Number of Products under Development by Companies, H2 2014 63
Number of Products under Investigation by Universities/Institutes, H2 2014 83
Comparative Analysis by Late Stage Development, H2 2014 87
Comparative Analysis by Clinical Stage Development, H2 2014 88
Comparative Analysis by Early Stage Products, H2 2014 89
Assessment by Monotherapy Products, H2 2014 345
Assessment by Combination Products, H2 2014 346
Number of Products by Top 10 Targets, H2 2014 347
Number of Products by Stage and Top 10 Targets, H2 2014 347
Number of Products by Top 10 Mechanism of Actions, H2 2014 359
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 359
Number of Products by Top 10 Routes of Administration, H2 2014 370
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 370
Number of Products by Top 10 Molecule Types, H2 2014 372
Number of Products by Stage and Top 10 Molecule Types, H2 2014 372

【掲載企業】

4SC AG
AB Science
AbbVie Inc.
Ablynx NV
Acceleron Pharma, Inc.
AcurePharma AB
Addex Therapeutics Ltd
Advinus Therapeutics Ltd.
Aegera Therapeutics Inc.
Agilvax, Inc.
Alder Biopharmaceuticals Inc.
Alloksys Life Sciences BV
Almirall, S.A.
AlphaMab Co., Ltd
Amgen Inc.
Amura Holdings Ltd.
Antyra, Inc.
Apexigen, Inc.
Aprogen, Inc.
arGentis Pharmaceuticals, LLC
Arrien Pharmaceuticals, LLC
Arthrogen BV
Asahi Kasei Pharma Corp.
Aslan Pharmaceuticals Pte. Ltd.
Astellas Pharma Inc.
AstraZeneca PLC
Auspex Pharmaceuticals, Inc.
Avesthagen Limited
Avexxin AS
Avipep Pty Ltd
Axxam SpA
Biocon Limited
Bioiberica, S.A.
Biokine Therapeutics Ltd.
Bionomics Limited
Biotest AG
BioTherapeutics Inc.
Biotie Therapies Corp.
Boehringer Ingelheim GmbH
Boehringer Ingelheim Pharmaceuticals, Inc.
Bolder Biotechnology, Inc.
Bone Medical Limited
Boryung Pharmaceutical Co., Ltd.
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd.
CASI Pharmaceuticals Inc.
CEL-SCI Corporation
Celgene Corporation
Cellceutix Corporation
Cellmid Limited
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Cellworks Group, Inc.
CG Pharmaceuticals, Inc.
ChemoCentryx, Inc.
Chipscreen Biosciences Ltd
ChironWells GmbH
Chong Kun Dang Pharmaceutical Corp.
Chugai Pharmaceutical Co., Ltd.
CIMAB S.A.
CLL Pharma
Compugen Ltd.
Coronado Biosciences, Inc.
Covagen AG
Creabilis SA
Daiichi Sankyo Company, Limited
Diurnal Ltd
Dong-A Socio Group
Dynamix Pharmaceuticals Ltd.
Effimune SAS
Eisai Co., Ltd.
Eli Lilly and Company
Emergent BioSolutions Inc.
Enceladus Pharmaceuticals BV
Endocyte, Inc.
Ensemble Therapeutics Corporation
Epirus Biopharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Farmacija d.o.o. Tuzla
Five Prime Therapeutics, Inc.
Fountain Biopharma Inc.
Galapagos NV
GeneFrontier Corporation
Genentech, Inc.
Genor BioPharma Co., Ltd.
Genosco
Gilead Sciences, Inc.
GlaxoSmithKline plc
Griffin Discoveries BV
Handok Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Hanwha Chemical Co., Ltd.
Huabo Biopharm Co., Ltd.
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
IMMD Inc.
Immune Response BioPharma, Inc.
ImmunoFrontier, Inc.
Immupharma Plc
Inbiopro Solutions Pvt. Ltd.
Infinity Pharmaceuticals, Inc.
Innate Pharma SA
Innovent Biologics, Inc.
Inovio Pharmaceuticals, Inc.
Intas Pharmaceuticals Ltd.
Invion Limited
InvivoGen Therapeutics
Johnson & Johnson
Kadmon Corporation, LLC
KAEL-GemVax Co., Ltd.
KAHR medical Ltd.
Kainos Medicine, Inc.
Kineta, Inc.
LG Life Sciences, Ltd.
Lupin Limited
Lycera Corp.
Mabion SA
MacroGenics, Inc.
Mebiopharm Co., Ltd.
MedAnnex Ltd
MediGene AG
MedImmune, LLC
MENTRIK Biotech, LLC
Merck & Co., Inc.
Mesoblast Limited
Mitsubishi Tanabe Pharma Corporation
Mochida Pharmaceutical Co., Ltd.
ModiQuest B.V.
Morphotek, Inc.
Motif BioSciences, Inc.
MSM Protein Technologies, Inc.
Mycenax Biotech Inc.
Myungmoon pharmaceutical Co.,Ltd.
Navigen Pharmaceuticals, Inc.
Neovacs SA
Nichi-Iko Pharmaceutical Co., Ltd.
Novartis AG
NovImmune SA
Nuvo Research Inc.
Omeros Corporation
Oncobiologics, Inc.
OncoImmune, Inc.
Ono Pharmaceutical Co., Ltd.
Onyx Pharmaceuticals, Inc.
OPKO Health, Inc.
Opsona Therapeutics Ltd.
Orchid Chemicals & Pharmaceuticals Ltd
Panacea Biotec Limited
Paras Biopharmaceuticals Finland Oy
Paratek Pharmaceuticals, Inc.
Pepscan Therapeutics
Peptinnovate Limited
Pfenex Inc.
Pfizer Inc.
Pharmacyclics, Inc.
PharmaIN Corporation
Pharmedartis GmbH
Phenex Pharmaceuticals AG
Philogen S.p.A.
Piramal Enterprises Limited
Plexxikon Inc.
Progenra, Inc.
ProNoxis AB
ProtAb Ltd
Protalex, Inc.
Protalix BioTherapeutics, Inc.
Provid Pharmaceuticals, Inc.
PurGenesis Technologies Inc.
Qu Biologics Inc.
R-Pharm
Re-Pharm Limited
Reata Pharmaceuticals, Inc.
Recoly N.V.
RedHill Biopharma Ltd.
Regeneron Pharmaceuticals, Inc.
Reliance Life Sciences Pvt. Ltd.
ReveraGen BioPharma, Inc.
Rhizen Pharmaceuticals SA
Richter Gedeon Nyrt.
Rottapharm SpA
RuiYi Inc.
Salix Pharmaceuticals Ltd.
Sandoz Inc.
Santen Pharmaceutical Co., Ltd.
SBI Biotech Co., Ltd.
Selvita SA
Shanghai Henlius Biotech Co., Ltd.
Shanghai Pharmaceutical Co., Ltd.
Spectrum Pharmaceuticals, Inc.
SuppreMol GmbH
Synovo GmbH
Synta Pharmaceuticals Corp.
Syntrix Biosystems, Inc.
Takeda Pharmaceutical Company Limited
TechnoPhage SA
Teva Pharmaceutical Industries Limited
TG Therapeutics, Inc.
Theraclone Sciences, Inc.
TheraMAB LLC.
TiGenix NV
Toleranzia AB
Toyama Chemical Co., Ltd.
TxCell SA
UCB S.A.
ugichem GmbH
UNIZYME Laboratories A/S
Upsher-Smith Laboratories, Inc.
Vaccinex, Inc.
Vascular Biogenics Ltd.
Vertex Pharmaceuticals Incorporated
Vichem Chemie Research Ltd.
Vicore Pharma AB
vida therapeutics inc.
ViroStatics, srl
Vitae Pharmaceuticals, Inc.
Vivia Biotech, S.L.
XBiotech USA, Inc.
Xencor, Inc.
XL-protein GmbH
XTL Biopharmaceuticals Ltd.
Yuhan Corporation
Yungjin Pharm Ind. Co., Ltd.
Zydus Cadila Healthcare Limited
Zynerba Pharmaceuticals, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[関節リウマチ(Rheumatoid Arthritis):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆